

Article

Simplified Synthesis and Stability Assessment of Aflatoxin B₁-Lysine and Aflatoxin G₁-Lysine

Justin B. Renaud ^{1,*}, Jacob P. Walsh ^{1,2}  and Mark W. Sumarah ^{1,2,*} 

¹ London Research and Development Centre, Agriculture and Agri-Food Canada, London, ON N5V 4T3, Canada; jwalsh69@uwo.ca

² Department of Chemistry, University of Western Ontario, London, ON N6A 3K7, Canada

* Correspondence: justin.renaud@agr.gc.ca (J.B.R.); mark.sumarah@agr.gc.ca (M.W.S.)

Abstract: Aflatoxins B₁ (AFB₁) and G₁ (AFG₁) are carcinogenic mycotoxins that contaminate crops such as maize and groundnuts worldwide. The broadly accepted method to assess chronic human aflatoxin exposure is by quantifying the amount of aflatoxin adducted to human serum albumin. This has been reported using ELISA, HPLC, or LC-MS/MS to measure the amount of AFB₁-lysine released after proteolysis of serum albumin. LC-MS/MS is the most accurate method but requires both isotopically labelled and unlabelled AFB₁-lysine standards, which are not commercially available. In this work, we report a simplified synthetic route to produce unlabelled, deuterated and ¹³C₆ ¹⁵N₂ labelled aflatoxin B₁-lysine and for the first-time aflatoxin G₁-lysine. Additionally, we report on the stability of these compounds during storage. This simplified synthetic approach will make the production of these important standards more feasible for laboratories performing aflatoxin exposure studies.

Keywords: aflatoxin; biomarker; aflatoxin B₁-lysine; aflatoxin G₁-lysine

Key Contribution: A straight forward synthetic pathway for AFB₁-Lys is presented. A new AFG₁-Lys isotopically labelled standard is also presented.



Citation: Renaud, J.B.; Walsh, J.P.; Sumarah, M.W. Simplified Synthesis and Stability Assessment of Aflatoxin B₁-Lysine and Aflatoxin G₁-Lysine. *Toxins* **2022**, *14*, 56. <https://doi.org/10.3390/toxins14010056>

Received: 18 December 2021

Accepted: 11 January 2022

Published: 14 January 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.




Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Aflatoxins are the most important mycotoxins from a human health perspective, especially in developing countries. It is estimated that over 500 million people in parts of Asia, Latin-American, and sub-Saharan Africa are being exposed to aflatoxin B₁ (AFB₁) mainly through the consumption of maize and groundnuts infected with *Aspergillus flavus* and/or *A. parasiticus* [1–3].

AFB₁ is highly mutagenic, arising from epoxidation of the 8,9 vinyl double bond by human liver P450 enzymes (CYP3A4, CYP1A2, and CYP3A5 in some individuals) [4]. AFB₁-8,9 exo-epoxide is considered to be one of the most carcinogenic compounds known [5]. It efficiently chelates between DNA base pairs to react with guanine residues leading to base pair mutations [6]. Ingested AFB₁ can also be transformed enzymatically into hydroxylated metabolites, such as AFM₁, which is far less mutagenic, although it is genotoxic [7,8] or to AFB₁-N⁷-guanine, which is excreted in urine. The carcinogen AFB₁-8,9 exo epoxide hydrolyzes rapidly under aqueous conditions to AFB₁-dihydrodiol which is in equilibrium with AFB₁-dialdehyde [9] (Scheme 1). AFB₁-dialdehyde is highly reactive towards amines [10] and forms covalent adducts with lysine residues within human serum albumin [11–13].



Scheme 1. When ingested, AFB₁ is metabolized by human P450 liver enzymes into the carcinogen 8,9 *exo*-AFB₁ epoxide. AFB₁-epoxide either reacts with DNA or hydrolyzes to AFB₁-dihydrodiol. AFB₁-dihydrodiol is in equilibrium with AFB₁-dialdehyde, which can form an adduct with lysine (Lys) in serum albumin. AFB₁-Lys can be quantified by releasing it from serum albumin following treatment with Pronase. AFB₁ can also be converted chemically to AFB_{2a} under acidic conditions, which rearranges into AFB_{2a}-dialdehyde and can react with free amines. Common AFB₁ biomarkers are shown in bold.

Aflatoxin exposure can be determined by monitoring the urinary metabolites AFM₁ and AFB₁-N⁷-guanine; however, this only accounts for exposures for the preceding day or two. Although these urinary metabolites have frequently been utilized as biomarkers for hepatocellular carcinoma risk, these associations are weak [14,15]. The most robust biomarker for aflatoxin exposure is the AFB₁-albumin adduct (AFB₁-alb) [16]; the half-life of serum albumin (~21 d) [17] makes it an average of chronic exposure during the past month [1]. Although unmetabolized AFB₁ can be detected in the urine, it is not believed to be strongly correlated with aflatoxin exposure [15].

Given the importance of aflatoxin on a global health scale, accurate and standardized methods to quantify the AFB₁-adduct are critical, yet there are key shortcomings that still need to be addressed. Specifically, the lack of commercially available analytical aflatoxin biomarker standards and well characterized quality control reference material are major obstacles when comparing and interpreting findings across multiple studies.

The AFB₁-alb adduct has been measured using ELISA [18,19], HPLC-fluorescence [20,21], and LC-MS/MS [22] by quantifying AFB₁-Lys released by enzymatic digestion. ELISA based measurements have historically reported higher concentrations than HPLC-based approaches or LC-MS/MS by a factor of 2.6 [23]. Although the reason for this discrepancy between methods is unknown, cross-reactivity with other aflatoxin-serum adducts may be responsible. Similar to AFB₁, aflatoxin G₁ produced by *A. parasiticus* is an order of magnitude less carcinogenic in animals than B₁ (Ayers et al. 1971; Butler et al. 1969). Aflatoxin G₁ can also be metabolized to a mutagenic epoxide [24] and can result in formation of AFG₁-alb adducts, although they have yet to be reported in humans [25].

AFB_{2a} is produced via acid hydrolysis of AFB₁ (Scheme 1) [26–28], and has been detected as a major urinary metabolite in some human studies [29]. Since it is missing the critical 8,9 vinyl double bond, AFB_{2a} is significantly less carcinogenic than AFB₁ [7]. However, similar to the AFB₁-epoxide, it can also rearrange to an amine reactive dialdehyde structure [30,31]. As with AFG₁, albumin adducts of AFB_{2a} have not yet been detected in human populations, although it has been suggested they exist [32].

Direct analytical methods such as LC-MS/MS and HPLC require an analytical standard, which to date has been exclusively AFB₁-Lys, and therefore, there are no data regarding the presence of other albumin adducts arising from AFB_{2a}, AFG₁, or even AFG_{2a}. The synthesis of AFB₁-Lys (reviewed in [33]), has generally followed a synthetic approach that mimics the *in vivo* route (Scheme 1). First, AFB₁ is epoxidized with either dimethyldioxirane [24,34], or *m*-chloroperbenzoic acid [35,36] to form the carcinogen AFB₁-epoxide. Synthesis of this intermediate is not without risk and requires careful handling. Following epoxidation, AFB₁-epoxide is then hydrolyzed to AFB₁-dialdehyde and coupled to free lysine [36]. In previous synthetic routes, the N α group of lysine has been protected by acetylation [10,37] or complexation with copper [34,38]. Once purified, the concentration of the analytical standard is determined by spectrophotometry using a molar attenuation coefficient ϵ_{399} 25,400/M·cm or ϵ_{400} 30,866/M·cm at pH 7.0 and 7.4, respectively [11,37]. To our knowledge, these molar attenuation coefficients are the sole basis for determining synthesized standard concentrations in subsequent studies, and it is unknown how any oxidized or degraded AFB₁-Lys present could affect these values.

Recently, a study examining potential interactions between AFB_{2a} and a number of free amino acids showed that AFB_{2a} could be coupled with lysine to form AFB_{2a}-Lys [31]. The authors showed that the addition of a strong oxidizing agent could convert AFB_{2a}-Lys to AFB₁-Lys. Although this was performed at a low concentration, this finding is significant for synthetic efforts since it would enable the highly carcinogenic AFB₁-epoxide intermediate to be bypassed.

In this work, we address one of the main shortcomings facing the determination of human exposure to AFB₁. We undertook a systematic approach to optimize a safer and simplified synthetic route for the production of AFB₁-Lys. We also expanded the synthesis from AFB₁-Lys to a total of four analytes that should be monitored in a single biological sample: AFB₁-Lys, AFB_{2a}-lysine, AFG₁-Lys, and AFG_{2a}-Lys. In addition, we generated isotopically labelled materials with Lysine-D₄ and Lysine ¹³C₆, ¹⁵N₂ to serve as internal standards. We then performed a stability assay to determine the best storage conditions for these important standards.

2. Results

2.1. Conversion of AFB₁ to AFB_{2a} and AFG₁ to AFG_{2a}

The efficient conversion of AFB₁ to the hemiacetal AFB_{2a} using 0.1 M citric acid at 28 °C in the range 24–48 h was reported by Ciegler et al. [28]. The authors also showed

that hydrolysis was likely occurring with AFG₁, but they could not isolate a sufficient quantity for confirmation. The hemiacetal AFB_{2a} can react readily with the amino groups of amino acids and proteins [39]. AFB_{2a} undergoes a structural rearrangement at alkaline pH (pKa 7.1) to form a phenolate ion with two aldehyde groups. These aldehyde groups are necessary for AFB_{2a} to couple with free amino groups [30].

We employed HCl as the acid source because its low vapor pressure allowed for effective removal by evaporation during the synthesis of AFB_{2a}. Over 48 h at 45 °C, AFB₁ was readily converted to AFB_{2a} under mild acidic conditions; the conversion of both AFB₁ and AFG₁ to AFB_{2a} and AFG_{2a}, were >95% (Figure 1)





Figure 1. Total ion current chromatogram (m/z 150–800) showing the conversion of AFB₁ (m/z 313) in 0.2 M HCl to AFB_{2a} (m/z 331) at (a) $t = 0$ h, (b) $t = 24$ h, and (c) $t = 48$ h. After 48 h at 45 °C it showed <5% AFB₁ remained by peak height intensity.

2.2. Coupling of AFB_{2a} or AFG_{2a} to Lysine

The equivalence point of the hemiacetal AFB_{2a} and AFB_{2a}-dialdehyde (Scheme 1) was measured and shown to occur at pH 7.1 [30]. As the dialdehyde form is necessary for the coupling of AFB_{2a} to amines, reaction conditions within the pH range 7–11 were investigated.

Following the addition of lysine to AFB_{2a} at a 2:1 molar ratio, the aqueous solutions developed into an intense yellow colour. Rushing et al. (2017) identified this coupling to be first order with respect to both reactants and that the reaction rate increased with increasing pH [31]. Lysine contains two primary amines that are able to couple with AFB_{2a} dialdehyde. In order to mimic the reactivity of AFB₁ dialdehyde within serum albumin lysine residues, it is necessary to direct the reaction towards the ϵ -amino group (Scheme 2). This was previously accomplished with AFB₁-dialdehyde by protecting the α -amino group by the use of N α -acetyl-lysine [10,37] or complexation of lysine with copper [34,38]. Reaction with

N α acetyl-lysine necessitates an additional treatment with acylase I. More recently, Sass and et al. showed that when AFB₁-dialdehyde was reacted with free lysine, the major product was the desired ϵ -group [36]. Here we closely monitored the effects of pH on the formation of either the α or ϵ -coupled AFB_{2a}-Lys.



Scheme 2. AFB_{2a}-dialdehyde can react with either amine groups of lysine. Within a polypeptide chain, only the ϵ -amino group is available to react and therefore the ϵ -coupled AFB_{2a}-Lys is the desired reaction product.

At pH 8.0, we observed the appearance of two isobaric peaks corresponding to the predicted formula of AFB_{2a}-Lys, C₂₃H₂₄N₂O₇ (Figure 2). The minor and earlier eluting peak corresponded to the AFB_{2a}-dialdehyde coupled to the α -amino group, whereas the major peak is the desired ϵ -linked product. The order of elution was determined by Rushing et al. (2017) who showed the later eluting peak was exclusively formed with acetyl-lysine reactant, whereas two peaks are observed with free lysine [31].

Figure 2c shows the ratio of the α/ϵ coupled AFB_{2a}-lysines as a function of pH. At pH 7–8.5, the ratio is fairly constant at $13 \pm 0.2\%$. This ratio decreases to $7 \pm 0.5\%$ at pH ≥ 9.5 . Although not dramatic, this trend closely follows the ratio of protonation for $\alpha\text{-NH}_3^+/\epsilon\text{-NH}_3^+$ (Figure 2c). At pH ≤ 9.5 , both amino groups of lysine are nearly fully protonated, yet the $\epsilon\text{-NH}_3^+$ is still highly favoured meaning that steric factors may greatly influence this preference of reactivity (Scheme 2).

Using a pH of 10.0 in subsequent experiments, a series of molar ratios between AFB_{2a} and lysine were investigated. In the absence of lysine, the λ_{max} of AFB_{2a} is 399 nm. Molar ratios of 1:1, 1:2, 1:4, and 1:10 AFB_{2a}:lysine were mixed and the UV–VIS signature taken after 5 min. A clear progression of λ_{max} was observed, with the 1:10 mixture having a λ_{max} of 406 nm (Figure 3a). Following incubation at room temperature for 30 min, all the AFB_{2a}:lysine ratios shifted to λ_{max} values between 406 and 408 nm (Figure 3b). When these solutions were tested by LC-MS, unreacted AFB_{2a} was not detected in any of the samples, while the intensity of the AFB_{2a}-Lys product was slightly lower in the 1:1 mixture compared to mixtures with excess lysine (Supplementary Materials, Figure S1). Therefore, for proceeding reactions, a 1:2 ratio of AFB_{2a}:lysine was used.




Figure 2. Extracted ion chromatograms for m/z 441 (AFB_{2a}-Lys) when the coupling reaction proceeds at (a) pH 8 and (b) pH 10. The minor, earlier eluting peak is the undesired α -amino linked AFB_{2a}-Lys while the major, less polar peak is the target ϵ -linked (c) AFB_{2a}-lys. Although AFB_{2a}- ϵ -Lys is the favoured product across the tested pH range, a higher pH favours its production and is associated to the degree of protonation.

2.3. Oxidation of AFB_{2a}-Lys to AFB₁-Lys

Rushing et al. (2017) used Oxone[®] to demonstrate that AFB_{2a}-Lys could be converted to AFB₁-Lys via the addition of single oxygen atom [31]. It has been suggested that if AFB_{2a}-alb adducts are present in vivo, its oxidation via natural biochemical processes may result in the formation of AFB₁-alb [32], bypassing the formation of AFB₁-epoxide (Scheme 1). Therefore, in addition to optimizing this final oxidation step using Oxone[®], we also investigated H₂O₂ due to its presence in cells as a short-lived metabolic by-product.

A small amount of AFB_{2a}-Lys (10 μ g AFB₁ equivalents) was dried down and reconstituted in 195 μ L of the 9 various solvents and buffers. A molar ratio of 1:10 AFB_{2a}-Lys:H₂O₂ resulted in limited observable changes whereas 1:100 AFB_{2a}-Lys:H₂O₂ and 1:1 AFB_{2a}-Lys:Oxone[®] resulted in the appearance of new products. In addition to unreacted AFB_{2a}-Lys, and the desired AFB₁-Lys (I), AFB₁-Lys with an additional oxygen (Scheme 3, II) and AFB₁-Lys with an additional double bond and oxygen (Scheme 3, III) were significant by-products. These unknown oxidation products were examined by high resolution LC-MS/MS (Figure 4) and their structures are proposed in Scheme 3.





Figure 3. A series of molar ratios between AFB_{2a} :lysine were investigated by UV–VIS at (a) 5 min post lysine addition and (b) 30 min post lysine addition. A clear progression of λ_{max} was observed at the 5 min mark, whereas after 30 min, all mixtures possessed similar spectra with λ_{max} values between 406 and 408 nm.



Scheme 3. Observed oxidation products following the addition of Oxone[®] or H_2O_2 to AFB_{2a} -Lys.




Figure 4. High resolution LC-MS/MS of (a) AFB_{2a}-Lys, (b) I; AFB₁-Lys, (c) II; AFB₁-Lys+O and (d) III; AFB₁-Lys+O-2H. MS/MS dissociation pathways (b–d) show multiple product ions are formed, whereas the AFB_{2a}-Lys, which does not possess a oxidized pyrrole ring, has one major product ion, that results from the loss of both H₂CO₂ and NH₃ from the lysine amino acid. All compounds have a *m/z* 84.0814 product ion derived from the Lys residue.

To systematically determine the best oxidizing agent for this reaction, we examined by LC-MS, both Oxone[®] and H₂O₂ under various reaction conditions (Figures 5 and 6).

For Oxone[®], a significant level of oxidation occurs at a molar ratio of 1:1, however this reaction is pH dependant. At pH 8, a maximum amount of AFB₁-Lys is produced, while by-products II and III still account for approximately 30% of the products generated (Figure 5a). Increasing the amount of Oxone[®] used results in a decrease in unreacted AFB_{2a}-Lys, however there is also an increase in the by-products with an added oxygen atom. Additionally, although the proportion of the desired AFB₁-Lys product does increase with increasing Oxone[®], the overall signal decreases (Figure 5c). This may be the result of the formation of pyrrole products that are able to polymerize [40].




Figure 5. Proportion of the various unreacted and oxidized AF-Lys products produced by (a) 1:1 AFB_{2a}-Lys: Oxone[®] and (b) 1:10 AFB_{2a}-Lys: Oxone[®]. Overall adding Oxone[®] to a reaction does increase the relative purity of AFB₁-Lys, (c) its overall intensity is dramatically decreased in this step.

When H₂O₂ is added at a 1:10 ratio, limited conversion of AFB_{2a}-Lys to AFB₁-Lys was observed, however at a higher ratio, there was efficient oxidation. Notably, when performed in methanol, the reactant was nearly completely consumed and converted mostly to AFB₁-Lys. The unwanted oxidized by-products (Scheme 3), were also minimized under these conditions. Increasing the pH of the reaction solution, did coincide with an increased quantity of oxidized by-products (Figure 6b). Unlike with Oxone[®], H₂O₂ added to a methanolic solution did not greatly decrease the overall signal of the desired product AFB₁-Lys. This may be due to conditions which do not favour polymerization (Figure 6c). Therefore, we determined that the most efficient route of converting AFB_{2a}-Lys to AFB₁-lys is via the addition of H₂O₂ in a methanolic solution.




Figure 6. Proportion of the various unreacted and oxidized AF-Lys products produced by (a) 1:100 AFB_{2a}-Lys: H₂O₂ and (b) 1:1000 AFB_{2a}-Lys: H₂O₂. (c) Overall additional H₂O₂ to a reaction performed in methanol did dramatically decrease the intensity of the desired product.

2.4. Synthesis of Isotopically Labelled Standards

The analysis of AFB₁-Lys by LC-MS/MS relies on isotopically labelled internal standards to account for sample matrix effects and analyte loss during sample cleanup. Previous studies used lysine-D₄ [38], whereas we used ¹³C₆, ¹⁵N₂ lysine [34]. In this work, using the optimized synthetic route described above, we were able to efficiently produce both AFB₁-Lys and AFG₁-Lys using unlabelled, deuterated and ¹³C₆, ¹⁵N₂ lysine for a total of six standards (Figure 7). A minimum of one internal standard per analyte is required to quantify these analytes in samples, however having two distinct isotopically labelled standards will allow for an additional performance step such as SPE or the Pronase[®] digestion to be monitored.




Figure 7. High resolution LC-MS/MS spectra of (a) AFB₁-Lys, (b) AFB₁-Lys-D₄, (c) AFB₁-Lys-¹³C₆, ¹⁵N₂, (d) AFG₁-Lys, (e) AFG₁-Lys-D₄, (f) AFB₁-Lys-¹³C₆, ¹⁵N₂.

2.5. Quantitative NMR

To our knowledge, the concentrations of synthetically derived AFB₁-Lys were determined by the molar attenuation coefficients described by Sabbioni (ϵ_{399} 25,400/M·cm at pH 7.0 [11] and ϵ_{400} 30,866/M·cm pH 7.4 [37]). During our first attempts to dissolve the isolated standards at concentrations at or above 1 mg/mL, we observed the formation of precipitates with methanol, D₂O, and D₂O with 0.01 M K₂DPO₄. These precipitates could not be resolubilized by changing the solvent, or with heating and sonication. Therefore, we aimed to perform qNMR at lower concentrations (0.5–1 mg/mL) and using a mixed solvent system that contained 70% D₂O and 30% MeCN-D₃.

Although spectroscopic quantitation is more straightforward than qNMR, if different groups synthesize standards that contain oxidized impurities, these molar attenuation coefficients may not accurately describe the concentration of synthetic AFB₁-Lys standards. Furthermore, should the standards undergo oxidation or degradation while in storage, checking the standard by spectrophotometry alone could also lead to inaccuracies. In this work, we undertook qNMR, using maleic acid as an internal standard. (Table 1).

Table 1. Comparison of Concentrations Derived from UV-VIS and qNMR.

Compound	ϵ (pH 7.4)	Concentration by UV-VIS (mM)	Concentration by qNMR (mM)
AFB ₁ -Lys	30,866	1.15	1.01
AFG ₁ -Lys	27,783	0.634	1.89

We observed good agreement between concentrations of AFB₁-Lys measured with UV-VIS and qNMR. This is significant as to our knowledge, all studies that have measured AFB₁-Lys in samples have relied on standards that have been characterized by the published molar attenuation constant and therefore, are likely accurate. This contrasts with our results for AFG₁-Lys, where we observed a significant disagreement between UV-VIS and qNMR derived concentrations. The UV-Vis AFG₁-Lys concentration was lower (%) than the concentrations determined by qNMR; 1.89 vs. 0.634 mM, respectively. We re-examined this disagreement by recording the mass of the dried AFG₁-Lys material in a pre-weighed vial, and resolubilizing the solution in 25% acetonitrile at 1 mg/mL. Similar to the qNMR comparison, UV-Vis concentrations were significantly less than what was expected based on the measured masses. The solution of AFG₁-Lys that was 1 mg/mL by mass, gave a measured concentration of only 0.3 mg/mL by UV-Vis. Therefore, the molar attenuation constant previously reported for AFG₁-Lys is likely not accurate and should not be used [25]. To our knowledge, AFG₁-Lys has not been measured as a biomarker in any populations and therefore this discrepancy has likely had limited impact on any published studies.

2.6. Stability

The stability of AFB₁-Lys was assessed in a 21 day assay under various conditions. The standard at 50 ng/mL was initially tested in various solvents, where it was found that it rapidly degraded in DMSO and had limited solubility in acetonitrile. Therefore, these two conditions were omitted from the full 21-day assay. With the exception of being stored as a dried residue with PBS salts, after 14 days (Figure 8a), the analyte was stable in all tested conditions when kept at −20 °C or 4 °C. Conversely, at 25 °C, degradation was observed in all solvents with the exception of methanol. The most significant degradation was observed when the analyte was stored in PBS, as a dried residue, or a dried residue with PBS salts. Therefore, these synthetic AFB₁-Lys and AFG₁-Lys standards if possible should not be shipped or transported as a dry residue.




Figure 8. Cont.




Figure 8. Stability of AFB₁-Lys over 21 days at −20 °C, 4 °C, and 25 °C. (a) The stability at t = 14 d is shown for PBS, methanol, 50% acetonitrile as well as dried residue and dried residue + PBS salt. The stability from 0–21 d at different temperatures is shown for standards in (b) 50% ACN and (c) methanol.

A closer inspection on the stability of AFB₁-Lys over 21 days in 50% acetonitrile or methanol (Figure 8b,c) indicates good stability can be maintained at colder temperatures across the tested time frame. At lower concentrations, the standards could be stored in methanol, however based on observations that insoluble precipitates could form in methanol at higher concentrations, storing the standards in a 50:50 water:acetonitrile solution is preferred for long term storage.

3. Conclusions

In this study we simplified the synthesis of AFB₁-Lys and presented the synthesis of AFG₁-Lys for the first time. We also produced Lysine-D₄ and Lysine ¹³C₆, ¹⁵N₂ labelled versions of both and studied their stability under a number of conditions. Access to these standards that are not commercially available is critical for conducting human aflatoxin exposure assessments. The next steps moving beyond this study are to develop a serum reference material and conduct a validation study comparing the currently available AFB₁-Lys standards. This will ensure better cooperation between laboratories conducting aflatoxin exposure assessments and will also ensure that data are comparable from one study to the next, which is critical for studies conducted on human populations.

4. Materials and Methods

4.1. Materials

AFB₁ and AFG₁ were obtained from Toronto Research Chemicals (Toronto, ON, Canada). Sodium bicarbonate, 50% hydrogen peroxide solution, Oxone[®], L-Lysine, L-Lysine-4,4,5,5-D₄, hydrochloride, L-Lysine-¹³C₆, ¹⁵N₂ hydrochloride, D₂O, acetonitrile-D₃, and maleic acid (qNMR standard, TraceCert[®]) were obtained from Millipore Sigma (Oakville, ON, Canada). LC-MS grade solvents H₂O, methanol, and acetonitrile were purchased from Fisher Scientific (Ottawa, ON, Canada).

LC-MS and high-resolution LC-MS/MS, all reactions were monitored using a Thermo Vanquish Duo UHPLC system coupled to a Thermo Altis triple quadrupole mass spectrometer. The UHPLC used an Agilent Zorbax C-18 column (50 × 2.1 mm; 1.8 μm) held at 35 °C, flow rate of 300 μL/min, aqueous mobile phase (A) of H₂O + 0.1% formic Acid (Fisher Optima[™] LC/MS Grade) and organic mobile phase (B) of acetonitrile + 0.1% formic acid (Fisher, Optima[™] LC/MS Grade) was used throughout. The gradient began with 2% B for 1.6 min before increasing to 100% over 2.4 min. B was held at 100% for 1 min before returning to 2% in 0.5 min. The analytes were monitored using an HESI source, in positive ionization full MS mode, with a range of *m/z* 150–800, scan rate of 1000 mass units/s, and resolution of 0.7 FWHM.

High resolution MS/MS spectra of analytes were obtained using a Q-Exactive Orbitrap mass spectrometer coupled to an Agilent 1290 UHPLC system. The chromatographic conditions were the same as previously described. Mass spectrometer analysis in positive mode was performed using the following conditions: heated electrospray ionization (HESI): capillary temperature, 400 °C; sheath gas, 17 arbitrary units; auxiliary gas, 8 units; probe heater temperature, 450 °C; S-Lens rf level, 45%; and capillary voltage, 3.9 kV. Analytes were analyzed by data-dependent analysis that included a full MS scan at 35,000 resolution, automatic gain control of 5×10^5 , followed by 3 MS/MS scans at 17,500 resolution, and normalized collision energy of 30.

4.2. Conversion of AFB₁/AFG₁ to AFB_{2a}/AFG_{2a}

AFB₁ and AFG₁ were converted to their '2a' equivalents following the method of Ciegler et al. [28] with some modifications. One mg of each aflatoxin standard was placed in an amber HPLC vial and dissolved in 0.4 mL of LC-MS grade acetonitrile. The solution was vortexed for 10 s and sonicated in a 25 °C water bath for 3 min to ensure the compound was completely dissolved. A 0.5 mL aliquot of LC-MS grade H₂O was added to the solution followed by 100 µL of 2 M HCl for a final acid concentration of 0.2 M. The vials were then placed on a thermomixer held at 42 °C with shaking at 300 rpm for 48 h. Following the incubation procedure, a 10 µL aliquot was removed and diluted in 990 µL of 50% acetonitrile and analyzed by LC-MS to ensure conversion was greater than 95% based on relative peak areas.

The resulting solutions were dried under a gentle stream of nitrogen gas at ambient temperature without additional heat. A 400 µL aliquot of acetonitrile was added to the residue and dried again to ensure that all residual acid was evaporated as it can negatively affect the coupling step. The dried aflatoxin residue was reconstituted in 50% acetonitrile at 1 mg/mL. Ten µL of this solution (10 µg AFB₁ equivalents) was transferred into the wells of a costar® 250 µL 96 well plates (Product: 3596, Corning Inc. Corning, New York, NY, USA), and dried under a gentle stream of nitrogen without heat. The subsequent coupling step was performed immediately after the residue was dried.

4.3. Coupling of Lysine to AFB_{2a}

L-Lysine was dissolved in LC-MS grade H₂O at a stock concentration of 1.9 mg/mL. Solutions of 0.05 M sodium bicarbonate were pH adjusted with either HCl or NaOH to 7.0, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, and 11 (± 0.1). Then 195 µL of H₂O, methanol, acetonitrile, or the buffers at the various pHs were added individually to the wells of a 96 well plate that contained 10 µg of the dried AFB_{2a} residue. A 5 µL aliquot of the 1.9 mg/mL lysine solution (9.4 µg) was added for a molar ratio of 1:2 AFB_{2a}:Lysine and aspirated to ensure that any dried residue was solubilized. The plate was incubated at room temperature for 30 min. Ten µL aliquots were removed and diluted with 90 µL of 50% acetonitrile before being analyzed by LC-MS.

An equivalent experiment was performed in 0.05 M sodium bicarbonate buffer (pH 10.0 \pm 0.1) and the volume of lysine was altered to obtain a molar ratios of AFB_{2a}:Lysine of: 1:0 (25 µL H₂O); 1:1 (2.5 µL Lys, 22.5 µL H₂O); 1:2 (5 µL Lys, 20 µL H₂O); 1:4 (10 µL Lys, 15 µL H₂O), and 1:10 (25 µL Lys). The UV-VIS spectra in the range 220–800 nm were collected at 5 min and 30 min post addition of lysine using a Thermo Multiskan™ GO microplate spectrophotometer.

A scale up reaction was performed using 100 µg of dried AFB_{2a} material in an amber glass vial, to which 195 µL of 0.05 M sodium bicarbonate (pH 10.0 \pm 0.1) was added and 5 µL of lysine at 19 mg/mL in H₂O. The solution was incubated at room temperature for 30 min and a 10 µL aliquot was removed, diluted in 990 µL of 50% acetonitrile and analyzed by LC-MS. A similar approach to the scale up described above was used for the production of AFB_{2a}-Lys-D₄, AFB_{2a}-Lys-¹³C₆¹⁵N₂, AFG_{2a}-Lys, AFG_{2a}-Lys-D₄, and AFG_{2a}-Lys-¹³C₆¹⁵N₂.

4.4. Oxidation of AFB_{2a}-Lysine to AFB₁-Lysine

Twenty μL ($\sim 10 \mu\text{g}$ AFB₁ equivalents) of AFB_{2a}-Lys prepared from the scale-up reaction described above was transferred into a 96 well plate and dried under a gentle stream of nitrogen without heat. 0.05 M dipotassium hydrogen phosphate (K₂HPO₄) was adjusted to pH 5 and pH 6; while 0.05 M sodium bicarbonate buffer was adjusted to pH 7, 8, 9, 10, and 11; all buffers were pH adjusted with either NaOH or HCl. The dried AFB_{2a}-Lys was reconstituted in 195 μL of methanol, H₂O, or the seven buffers listed above. The residue could not be fully resolubilized in pure acetonitrile, which was not included in this experiment.

Oxone[®] (MW 152.2 Da) was dissolved in H₂O at a concentration of 9.75 mg/mL (Oxone 10X). A portion of this solution was diluted with H₂O to a concentration of 0.98 mg/mL (Oxone 1X). H₂O₂ (50% *v/v*, $\rho = 1.197 \text{ g/mL}$) was diluted into H₂O to a concentration of 18.3% (*v/v*) (H₂O₂ 1000x). This solution was further diluted to 1.8% (H₂O₂ 1X). Individually, 5 μL of either Oxone 10X, Oxone 1X, H₂O₂ 1000X, and H₂O₂ 100X were added to the dissolved AFB_{2a}-Lys in the various solutions. The 1X represents a 1:1 molar ratio between the AFB_{2a}-Lys and the Oxone[®], the 10X solutions represent a 1:10 molar ratio. Similarly, 100x and 1000x represent a 1:100 and 1:1000 molar ratio between AFB_{2a}-Lys and H₂O₂. Five μL of the stock 50% H₂O₂ solution added directly to the dried AFB_{2a}-Lys material represented a 1:27,512 molar ratio between the AFB_{2a}-Lys and the oxidant, respectively. The solutions with the oxidants were incubated at room temperature for 1 h with shaking at 300 rpm.

In a scale up reaction, dried AFB_{2a}-Lys residue (100 μg AFB₁ equiv.) in an amber glass vial, were resolubilized in 195 μL of MeOH and vortexed for 15 s. Five μL of 1000X H₂O₂ was added and the solution was incubated at room temperature for 1 h. The reaction mixture was then dried down under nitrogen gas without heat to remove any residual H₂O₂.

A similar approach to the scale up described above was used for the production of AFB₁-lysine-D₄, AFB₁-Lys-¹³C₆¹⁵N₂, AFG₁-Lys, AFG₁-Lys-D₄, AFG₁-Lys-¹³C₆¹⁵N₂. A stepwise synthesis protocol is included in Supplementary Information (Table S1).

4.5. Purification by HPLC

The reaction products were isolated with an Agilent 1200 HPLC system (Supplementary Materials, Figure S2). Chromatographic conditions included an Eclipse XDB-C18 (9.4 \times 250 mm, 5 μm ; Agilent Technologies) column maintained at 35 °C with 100 μL injection volume. A 20-min gradient program consisting of a mobile phase of water with 0.1% trifluoroacetic acid (Sigma) (mobile phase A) and acetonitrile with 0.1% trifluoroacetic acid (mobile phase B) (Optima grade, Fisher Scientific) with a flow rate of 4 mL/min. The gradient began at 5% B, was held for 2 min, then increased to 45% B over 13 min, followed by an increase to 100% B over 0.5 min, then held at 100% B for 2.5 min. The method was completed by reconditioning the system to 5% B over 0.5 min and holding at 5% B for 1.5 min. Fractions were collected using time points established by analyzing the HPLC-UV spectra at 399 nm.

4.6. Quantitative NMR

Purified AFB₁-Lys and AFG₁-Lys were dried and reconstituted in D₂O:acetonitrile-D₃ (70:30 for AFB₁-Lys and 75:25 for AFG₁-Lys). A 25 μL aliquot was diluted in 975 μL of 0.1 M phosphate buffer (pH 7.4) and the concentrations were approximated by UV-VIS. The concentration of the AFB₁-Lys solution approximated by UV-Vis using $\epsilon_{400} 30,866/\text{M}\cdot\text{cm}$ [37] while AFG₁-Lys was approximated using $\epsilon_{413} 27,783/\text{M}\cdot\text{cm}$ [25]. Using this initial concentration, maleic acid (TraceCert[®], Millipore, Sigma) dissolved in D₂O was added to the aflatoxin standards to achieve a molar ratio with the aflatoxin-Lys adducts in the range 1:1–1:2 based on UV absorbance values.

Quantitative NMR (qNMR) data were obtained on a Varian 600 (I600) (Agilent Technologies, Santa Clara, CA, USA) with an Auto-XBD probe. The solvent system was D₂O:

acetonitrile-D₃ (70:30 for AFB₁-Lys and 75:25 for AFG₁-Lys), and the NMR was locked to D₂O. A five second relaxation delay was set, with a pulse angle of 45° with 256 scans at ambient temperature (22 °C). Quantitation was performed using five signals that were averaged and compared to the ¹H NMR chemical shifts for maleic acid. The AFB₁-Lys signals used were δ 2.57 (2H, integration: 2.00), δ 3.89 (2H, integration: 2.03), δ 3.37 (2H, integration: 1.97), δ 2.20 (1H, integration: 0.97), δ 3.45 (1H, integration: 1.04), averaged to 1.002 ± 0.024 per 1H, maleic acid was integrated for δ 3.20 (2H) or δ 1.60 (1H). For AFG₁-Lys the signals used were δ 3.79 (1H, integration: 0.94), δ 3.45 (1H, integration: 1.00), δ 3.17 (2H, integration: 2.07), δ 1.78 (1H, integration: 1.06), δ 1.63 (2H, integration: 2.04), averaged to integration of 1.011 ± 0.041 per 1H, maleic acid was integrated for 0.670 (2H) or 0.335 (1H).

Using the qNMR derived concentrations, the solutions were diluted into 50% acetonitrile at a concentration of 10 µg/mL and transferred to Thermo Scientific Matrix barcoded storage tubes and stored at −80 °C.

4.7. Stability Assay

A solution of AFB₁-Lys at 50 ng/mL was prepared in the following solvents: DMSO, 0.1M PBS (pH 7.4), methanol, H₂O, and 50:50 acetonitrile: water. Aliquots of 50 µL at these concentrations were placed in individual polypropylene tubes and store at −20 °C, 4 °C, and 20 °C in darkness. Additionally, 50 µL solutions of 50 ng/mL AFB₁-Lys in 0.1M PBS (pH 7.4) and H₂O were placed into polypropylene tubes, and dried down using a centrivap and also placed at either −20 °C, 4 °C, or 20 °C.

At various time points, the tubes containing the AFB₁-Lys were transferred to −80 °C and stored until the day of analysis. Prior to analysis, the samples were brought to room temperature and 10 µL of the 50 ng/mL solutions was transferred to fresh tubes and diluted with 90 µL of water. The peak areas of each time point at the various conditions and temperatures were normalized to the peak area of the *t*₀ sample which was stored at −80 °C for the entirety of the assay.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/toxins14010056/s1>, Figure S1, LC-MS/MS chromatogram of AFB_{2a} reacted with a molar ratio of 1 to (a) 0, (b)1, (c) 2, (d) 4, (e) 10 lysine; Figure S2, Chromatogram of isolation AFB₁-Lys was obtained using method described in Section 4.5. AFB₁-Lys peak of interest is highlighted and was collected using time-based fraction collected. All fractions were screened by LC-MS to confirm identification. Chromatogram obtained at 399 nm referenced to 460 nm; Table S1, Synthesis of Aflatoxin B₁-lysine (AFB₁-lysine).

Author Contributions: Conceptualization, J.B.R. and M.W.S.; methodology, J.B.R. and J.P.W. Writing—original draft preparation, J.B.R.; writing—review and editing, J.P.W. and M.W.S.; project administration, M.W.S.; funding acquisition, M.W.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by an AAFC grant #3022 to M.W.S.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The authors thank J. David Miller (Carleton) for a critical review of the manuscript and D. McMullin (Carleton) for helpful comments on this manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. *Evaluation of Certain Contaminants in Food: Eighty-Third Report of the Joint Fao/Who Expert Committee on Food Additives*; Joint Food and Agriculture Organization/World Health Organization: Geneva, Switzerland, 2017.
2. Pitt, J.I.; Wild, C.P.; Baan, R.A.; Gelderblom, W.C.; Miller, J.; Riley, R.; Wu, F. *Improving Public Health through Mycotoxin Control*; International Agency for Research on Cancer: Lyon, France, 2012.
3. Wild, C.P.; Miller, J.D.; Groopman, J.D. *Mycotoxin Control in Low-and Middle-Income Countries*; International Agency for Research on Cancer: Lyon, France, 2015.

4. Wojnowski, L.; Turner, P.C.; Pedersen, B.; Hustert, E.; Brockmöller, J.; Mendy, M.; Whittle, H.C.; Kirk, G.; Wild, C.P. Increased levels of aflatoxin-albumin adducts are associated with CYP3A5 polymorphisms in The Gambia, West Africa. *Pharmacogenet. Genom.* **2004**, *14*, 691–700. [[CrossRef](#)] [[PubMed](#)]
5. Harris, T.; Stone, M.; Gopalakrishnan, S.; Baertschi, S.; Raney, K.; Byrd, S. Aflatoxin B1 epoxide, the ultimate carcinogenic form of aflatoxin B1: Synthesis and reaction with DNA. *J. Toxicol. Toxin Rev.* **1989**, *8*, 111–120. [[CrossRef](#)]
6. Martin, C.N.; Garner, R.C. Aflatoxin B-oxide generated by chemical or enzymic oxidation of aflatoxin B1 causes guanine substitution in nucleic acids. *Nature* **1977**, *267*, 863–865. [[CrossRef](#)] [[PubMed](#)]
7. Wong, J.J.; Hsieh, D. Mutagenicity of aflatoxins related to their metabolism and carcinogenic potential. *Proc. Natl. Acad. Sci. USA* **1976**, *73*, 2241–2244. [[CrossRef](#)]
8. Theumer, M.G.; Henneb, Y.; Khoury, L.; Snini, S.; Tadriss, S.; Canlet, C.; Puel, O.; Oswald, I.P.; Audebert, M. Genotoxicity of aflatoxins and their precursors in human cells. *Toxicol. Lett.* **2018**, *287*, 100–107. [[CrossRef](#)] [[PubMed](#)]
9. Johnson, W.W.; Harris, T.M.; Guengerich, F.P. Kinetics and mechanism of hydrolysis of aflatoxin B1 exo-8, 9-epoxide and rearrangement of the dihydrodiol. *J. Am. Chem. Soc.* **1996**, *118*, 8213–8220. [[CrossRef](#)]
10. Guengerich, F.P.; Voehler, M.; Williams, K.M.; Deng, Z.; Harris, T.M. Structure of the aflatoxin B1 dialdehyde adduct formed from reaction with methylamine. *Chem. Res. Toxicol.* **2002**, *15*, 793–798. [[CrossRef](#)]
11. Sabbioni, G.; Skipper, P.L.; Büchi, G.; Tannenbaum, S.R. Isolation and characterization of the major serum albumin adduct formed by aflatoxin B1 in vivo in rats. *Carcinogenesis* **1987**, *8*, 819–824. [[CrossRef](#)] [[PubMed](#)]
12. Nassar, A.; Megalla, S.; Abd El-Fattah, H.; Hafez, A.; El-Deap, T. Binding of aflatoxin b1, g1 and m to plasma albumin. *Mycopathologia* **1982**, *79*, 35–38. [[CrossRef](#)]
13. Gan, L.-S.; Skipper, P.L.; Peng, X.; Groopman, J.D.; Chen, J.-S.; Wogan, G.N.; Tannenbaum, S.R. Serum albumin adducts in the molecular epidemiology of aflatoxin carcinogenesis: Correlation with aflatoxin B1 intake and urinary excretion of aflatoxin m 1. *Carcinogenesis* **1988**, *9*, 1323–1325. [[CrossRef](#)] [[PubMed](#)]
14. Ross, R.K.; Yu, M.; Henderson, B.; Yuan, J.-M.; Qian, G.-S.; Tu, J.-T.; Gao, Y.-T.; Wogan, G.; Groopman, J. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. *Lancet* **1992**, *339*, 943–946. [[CrossRef](#)]
15. Groopman, J.D.; Wild, C.P.; Hasler, J.; Junshi, C.; Wogan, G.N.; Kensler, T.W. Molecular epidemiology of aflatoxin exposures: Validation of aflatoxin-N7-guanine levels in urine as a biomarker in experimental rat models and humans. *Environ. Health Perspect.* **1993**, *99*, 107–113. [[CrossRef](#)]
16. Wild, C.; Turner, P. The toxicology of aflatoxins as a basis for public health decisions. *Mutagenesis* **2002**, *17*, 471–481. [[CrossRef](#)] [[PubMed](#)]
17. Nilsen, J.; Trabjerg, E.; Grevys, A.; Azevedo, C.; Brennan, S.O.; Stensland, M.; Wilson, J.; Sand, K.M.K.; Bern, M.; Dalhus, B. An intact C-terminal end of albumin is required for its long half-life in humans. *Commun. Biol.* **2020**, *3*, 1–11. [[CrossRef](#)]
18. Wild, C.P.; Jiang, Y.-Z.; Sabbioni, G.; Chapot, B.; Montesano, R. Evaluation of methods for quantitation of aflatoxin-albumin adducts and their application to human exposure assessment. *Cancer Res.* **1990**, *50*, 245–251. [[PubMed](#)]
19. Chapot, B.; Wild, C. ELISA for quantification of aflatoxin-albumin adducts and their application to human exposure assessment. *Tech. Diagn. Pathol.* **1991**, *2*, 135–155.
20. Wild, C.P.; Hudson, G.J.; Sabbioni, G.; Chapot, B.; Hall, A.J.; Wogan, G.N.; Whittle, H.; Montesano, R.; Groopman, J.D. Dietary intake of aflatoxins and the level of albumin-bound aflatoxin in peripheral blood in The Gambia, West Africa. *Cancer Epidemiol. Prev. Biomark.* **1992**, *1*, 229–234.
21. Xue, K.S.; Cai, W.; Tang, L.; Wang, J.-S. Aflatoxin B1-lysine adduct in dried blood spot samples of animals and humans. *Food Chem. Toxicol.* **2016**, *98*, 210–219. [[CrossRef](#)]
22. McCoy, L.F.; Scholl, P.F.; Schleicher, R.L.; Groopman, J.D.; Powers, C.D.; Pfeiffer, C.M. Analysis of aflatoxin B1-lysine adduct in serum using isotope-dilution liquid chromatography/tandem mass spectrometry. *Rapid Commun. Mass Spectrom.* **2005**, *19*, 2203–2210. [[CrossRef](#)]
23. Scholl, P.F.; Turner, P.C.; Sutcliffe, A.E.; Sylla, A.; Diallo, M.S.; Friesen, M.D.; Groopman, J.D.; Wild, C.P. Quantitative comparison of aflatoxin B1 serum albumin adducts in humans by isotope dilution mass spectrometry and elisa. *Cancer Epidemiol. Biomark. Prev.* **2006**, *15*, 823–826. [[CrossRef](#)]
24. Baertschi, S.W.; Raney, K.D.; Shimada, T.; Harris, T.M.; Guengerich, F.P. Comparison of rates of enzymic oxidation of aflatoxin b1, aflatoxin g1, and sterigmatocystin and activities of the epoxides in forming guanyl-N7 adducts and inducing different genetic responses. *Chem. Res. Toxicol.* **1989**, *2*, 114–122. [[CrossRef](#)]
25. Sabbioni, G.; Wild, C.P. Identification of an aflatoxin G1-serum albumin adduct and its relevance to the measurement of human exposure to aflatoxins. *Carcinogenesis* **1991**, *12*, 97–103. [[CrossRef](#)] [[PubMed](#)]
26. Purchase, I.; Steyn, M. The metabolism of aflatoxin B1 in rats. *Br. J. Cancer* **1969**, *23*, 800–805. [[CrossRef](#)] [[PubMed](#)]
27. Ruprich, J. Preparation and identification of aflatoxin B2a under laboratory conditions. *Vet. Med.* **1983**, *28*, 361–366.
28. Ciegler, A.; Peterson, R. Aflatoxin detoxification: Hydroxydihydro-aflatoxin B. *Appl. Microbiol.* **1968**, *16*, 665–666. [[CrossRef](#)] [[PubMed](#)]
29. Bean, T.; Yourtee, D.; Akande, B.; Ogunlewe, J. Aflatoxin metabolites in the urine of Nigerians comparison of chromatographic methods. *J. Toxicol. Toxin Rev.* **1989**, *8*, 43–52. [[CrossRef](#)]
30. Ashoor, S.H.; Chu, F.S. Reduction of aflatoxin B2a with sodium borohydride. *J. Agric. Food Chem.* **1975**, *23*, 445–447. [[CrossRef](#)]

31. Rushing, B.R.; Selim, M.I. Structure and oxidation of pyrrole adducts formed between aflatoxin B2a and biological amines. *Chem. Res. Toxicol.* **2017**, *30*, 1275–1285. [[CrossRef](#)]
32. Rushing, B.R.; Selim, M.I. Aflatoxin B1: A review on metabolism, toxicity, occurrence in food, occupational exposure, and detoxification methods. *Food Chem. Toxicol.* **2019**, *124*, 81–100. [[CrossRef](#)] [[PubMed](#)]
33. Cristina Sass, D.; Vincenzi Jager, A.; Gustavo Tonin, F.; Naira Zambelli Ramalho, L.; Silva Ramalho, F.; Gomes Constantino, M.; Augusto Fernandes Oliveira, C. Methods for chemical preparation of aflatoxin B1 adducts, AFB1-N7-guanine and AFB1-lysine. *Toxin Rev.* **2013**, *32*, 68–74. [[CrossRef](#)]
34. McMillan, A.; Renaud, J.B.; Burgess, K.M.; Orimadegun, A.E.; Akinyinka, O.O.; Allen, S.J.; Miller, J.D.; Reid, G.; Sumarah, M.W. Aflatoxin exposure in nigerian children with severe acute malnutrition. *Food Chem. Toxicol.* **2018**, *111*, 356–362. [[CrossRef](#)] [[PubMed](#)]
35. Iyer, R.S.; Harris, T.M. Preparation of aflatoxin B1 8, 9-epoxide using m-chloroperbenzoic acid. *Chem. Res. Toxicol.* **1993**, *6*, 313–316. [[CrossRef](#)] [[PubMed](#)]
36. Sass, D.C.; Jager, A.V.; Tonin, F.G.; Rosim, R.E.; Constantino, M.G.; Oliveira, C.A.F. Synthesis and purification of the aflatoxin B1-lysine adduct. *Toxin Rev.* **2015**, *34*, 53–59. [[CrossRef](#)]
37. Sabbioni, G. Chemical and physical properties of the major serum albumin adduct of aflatoxin B1 and their implications for the quantification in biological samples. *Chem.-Biol. Interact.* **1990**, *75*, 1–15. [[CrossRef](#)]
38. Scholl, P.F.; Groopman, J.D. Synthesis of 5, 5, 6, 6-D4-l-lysine-aflatoxin B1 for use as a mass spectrometric internal standard. *J. Label. Compd. Radiopharm.* **2004**, *47*, 807–815. [[CrossRef](#)]
39. Patterson, D.; Roberts, B. Aflatoxin metabolism in duck-liver homogenates: The relative importance of reversible cyclopentenone reduction and hemiacetal formation. *Food Cosmet. Toxicol.* **1972**, *10*, 501–512. [[CrossRef](#)]
40. Howard, J.K.; Rihak, K.J.; Bissember, A.C.; Smith, J.A. The oxidation of pyrrole. *Chem.-Asian J.* **2016**, *11*, 155–167. [[CrossRef](#)]